SCHEMBL4206367

SCHEMBL4206367

CC(C)OC(=O)c1ccccc1NC(=O)c1ccc(COc2ccccc2Cl)cc1.O=C(Nc1ccc(Br)cc1C(=O)O)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.53
HPGD P15428 4/20 0.53
KDM4E B2RXH2 4/20 0.53
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53
ALDH1A1 P00352 3/20 0.53
CTDSP1 Q9GZU7 1/20 0.48
NOD2 Q9HC29 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
AKR1C2 P52895 2/20 0.47
AKR1C1 Q04828 2/20 0.47
SCD O00767 1/20 0.46
MAPT P10636 4/20 0.46
CASP3 P42574 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
SENP7 Q9BQF6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2292116 0.86 KDM4E (0.63) SMN1; SMN2HPGDKDM4ENPC1RAB9A
SCHEMBL6351828 0.81 PTGES (0.62) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL4209179 0.77 AKR1C2 (0.56) SMN1; SMN2HPGDKDM4ENPC1RAB9A
SCHEMBL2290679 0.76 HPGD (0.78) SMN1; SMN2HPGDKDM4ENPC1RAB9A
SCHEMBL2290505 0.74 KDM4E (0.67) SMN1; SMN2HPGDKDM4ENPC1RAB9A
SCHEMBL4213146 0.73 AKR1C2 (0.61) SMN1; SMN2HPGDNPC1RAB9ACYP1A2
SCHEMBL1307965 0.73 AKR1C2 (0.77) SMN1; SMN2KDM4ENPC1RAB9AALDH1A1
SCHEMBL2290164 0.73 SMN1; SMN2 (0.76) SMN1; SMN2NPC1RAB9AALDH1A1MEN1
SCHEMBL4217129 0.73 AKR1C2 (0.54) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL1123502 0.73 SMN1; SMN2 (0.61) SMN1; SMN2HPGDKDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247637-A1 Novel Anthranilic Acid Derivatives GPR84, GPR88, HCAR1 SMN1; SMN2 3904/4885HPGD 1058/4885KDM4E 3132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.